Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 20/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1922490 | 0.99 | CHRM3 (0.80) | CHRM3 | |
| SCHEMBL13590462 | 0.93 | CHRM3 (0.90) | CHRM3 | |
| SCHEMBL13590186 | 0.93 | CHRM3 (0.90) | CHRM3 | |
| SCHEMBL13590343 | 0.93 | CHRM3 (0.90) | CHRM3 | |
| SCHEMBL13590261 | 0.93 | CHRM3 (0.90) | CHRM3 | |
| SCHEMBL13590412 | 0.93 | CHRM3 (0.90) | CHRM3 | |
| SCHEMBL13590176 | 0.93 | CHRM3 (0.90) | CHRM3 | |
| SCHEMBL13590397 | 0.93 | CHRM3 (0.90) | CHRM3 | |
| SCHEMBL266147 | 0.92 | CHRM3 (0.80) | CHRM3 | |
| SCHEMBL13590162 | 0.92 | CHRM3 (0.89) | CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011083387-A1 | HYDROCHLORIDE SALT OF BIPHENYL-2-YL-CARBAMIC ACID 1-{9-[(3-FLUORO-4-HYDROXY-BENZOYL)-METHYL-AMINO]-NONYL}-PIPERIDIN-4-YL ESTER | PFIZER LIMITED (GB) | 2011-07-14 | — | — | WO | disclosed |
| WO-2011083387-A1 | HYDROCHLORIDE SALT OF BIPHENYL-2-YL-CARBAMIC ACID 1-{9-[(3-FLUORO-4-HYDROXY-BENZOYL)-METHYL-AMINO]-NONYL}-PIPERIDIN-4-YL ESTER | PFIZER LIMITED (GB) | 2011-07-14 | — | — | WO | disclosed |
| EP-2328868-A1 | NOVEL COMPOUNDS ACTIVE AS MUSCARINIC RECEPTOR ANTAGONISTS | Pfizer Limited (GB) | 2011-06-08 | — | — | EP | disclosed |
| WO-2010007552-A1 | NOVEL COMPOUNDS ACTIVE AS MUSCARINIC RECEPTOR ANTAGONISTS | PFIZER LIMITED (GB) | 2010-01-21 | — | — | WO | disclosed |
| WO-2010007552-A1 | NOVEL COMPOUNDS ACTIVE AS MUSCARINIC RECEPTOR ANTAGONISTS | PFIZER LIMITED (GB) | 2010-01-21 | — | — | WO | disclosed |
| US-20100016366-A1 | Novel Compounds Active as Muscarinic Receptor Antagonists | GLOSSOP PAUL ALAN | 2010-01-21 | — | — | US | disclosed |
| US-20100016366-A1 | Novel Compounds Active as Muscarinic Receptor Antagonists | GLOSSOP PAUL ALAN | 2010-01-21 | — | — | US | disclosed |
| US-20100016366-A1 | Novel Compounds Active as Muscarinic Receptor Antagonists | GLOSSOP PAUL ALAN | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016366-A1 | Novel Compounds Active as Muscarinic Receptor Antagonists | CHRM3, CHRM2, CHRM5 | CHRM3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.